LeMaitre Vascular, Inc. (LMAT) Q4 2025 Earnings Call Transcript

SA Transcripts158.63K FollowersFollow5ShareSaveCommentsQ4: 2026-02-25 Earnings SummaryInsightsTranscript InsightsPlay CallPlay CallEPS of $0.68 beats by $0.02 | Revenue of $64.45M (15.68% Y/Y) beats by $1.63M LeMaitre Vascular, Inc. (LMAT) Q4 2025 Earnings Call February 25, 2026 5:00 PM EST Company Participants Dorian LeBlanc - Chief Financial OfficerGeorge LeMaitre - Chairman & CEODavid Roberts - President & Director Conference Call Participants Kyle Bauser - ROTH Capital Partners, LLC, Research DivisionFrederick Wise - Stifel, Nicolaus & Company, Incorporated, Research DivisionMichael Petusky - Barrington Research Associates, Inc., Research DivisionJakub Mlejnek - Oppenheimer & Co. Inc., Research DivisionMichael Sarcone - Jefferies LLC, Research DivisionBrett Fishbin - KeyBanc Capital Markets Inc., Research DivisionDaniel Stauder - Citizens JMP Securities, LLC, Research DivisionJames Sidoti - Sidoti & Company, LLC Presentation Operator Welcome to the LeMaitre Vascular Q4 2025 Financial Results Conference Call. As a reminder, today's call is being recorded. At this time, I would like to turn the call over to Mr. Dorian LeBlanc, Chief Financial Officer of LeMaitre Vascular. Please go ahead, sir. Dorian LeBlancChief Financial Officer Thank you. Good afternoon, and thank you for joining us on our Q4 2025 conference call. With me on today's call is our CEO, George LeMaitre; and our President, Dave Roberts. Before we begin, I'll read our safe harbor statement. Today, we'll be making some forward-looking statements within the meaning of the U.S.

Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risks and uncertainties. Wherever possible, we will try to identify those forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast and similar expressions. Our forward-looking statements are based on our estimates and assumptions as of today, February 25, 2026, and should not be relied upon as representing our estimates or views on any subsequent date. Please refer to the cautionary statement regarding forward-looking information and the risk factors in our most recent 10-K and subsequent SEC filings, including disclosure of the factors that could cause results to differ materially from those expressed or implied.